Health and BiotechSoftware
On-the-move support for schizophrenia - ACTISSIST
ACTISSIST is a new app developed at The University of Manchester to provide therapy on-the-move for those with severe mental illnesses such as schizophrenia.
Stop bugging me! - Antimicrobial peptides
Addressing concerns regarding super-resistant diseases which even the strongest medicines cannot touch, this peptide-packed technology is a remedy for the post-antibiotic age.
Targeted tumour treatment
Current clinical solutions are not as effective as they could be, with certain cancers and tumours evading treatment. This unmet need is being met with a Hypoxia-beating new drug.
The cellular level – eNAMPT stimulation
A build-up of Nicotinamide Adenine Dinucleotide (NAD) in the body can result in the onset of various diseases and poor health outcomes. The University of Manchester have developed a new series of small molecule compounds, specifically designed to stimulate eNAMPT dimerization and have demonstrated these have potent activity leading to a corrective effect in in vitro and in vivo phenotypic models of diabetes. These could also have benefits in the treatment of a number of other diseases.